Company intelligence / Profile preview

KBio

Ownership: Private
Development stage: Preclinical

Overview

KBio leverages its proprietary RP3 platform to rapidly develop high-purity antibody therapies and vaccines using plants. The company claims its approach enables faster progression to clinical studies compared to industry norms, with demonstrated ability to produce novel drug candidates at lower cost. Its pipeline includes both preclinical and early-stage clinical programs targeting rare diseases, infectious disease threats, and pandemic preparedness.

Therapeutic areas: Rare DiseasesInfectious Diseases
Modalities: Antibodies (including monoclonal antibodies)VaccinesRecombinant proteins and bioactive compounds produced via plant expression systems
Industry: Biotech

Drug pipeline

6 assets

EV68-228-N

5 more assets in the full pipeline.

Partnerships

Strategic global partnerships for technology optimization; specific partners not named publicly but includes collaboration with Kentucky BioProcessing Inc.

Beyond the preview

Go deeper on KBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBio.